IndiaTickerTransgene Biotek Ltd - 526139 - Board Meeting Intimation for Intimation Of The Board Meeting.BSE · exchange filing · pdf
Source filing Company dossier
Transgene Biotek
BSE:TRABI · ISIN INE773D01018
- Close
- Unavailable Date unavailable
- Daily change
- N/A Exchange close
- Evidence state
- Building 0/0 checks
Transgene Biotek
Filings
Preserved evidence
40 recent eventsPrimary-source filing timeline
Transgene Biotek Ltd - 526139 - Statement Of Deviation & VariationBSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Compliance-57 (4) : Prior intimation to the beginning of the quarterBSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Compliance-57 (5) : intimation after the end of quarterBSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018BSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Closure of Trading WindowBSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Announcement under Regulation 30 (LODR)-Newspaper PublicationBSE · financial results · pdf
Source filing Transgene Biotek Ltd - 526139 - Outcome Of Board Meeting And Submission Of Audited Financial Results For The Fourth Quarter And Financial Year Ended March 31, 2026BSE · financial results · pdf
Source filing Transgene Biotek Ltd - 526139 - Board Meeting Outcome for Outcome Of Board Meeting And Submission Of Audited Financial Results For The Fourth Quarter And Financial Year Ended March 31, 2026BSE · financial results · pdf
Source filing Transgene Biotek Ltd - 526139 - Board Meeting Intimation for Intimation Of The Board Meeting Of The Company -
This Is To Inform You That A Meeting Of Board Of Directors Of The Company Will Be Held On Friday 29Th May 2026.BSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Compliance Certificate Pursuant To Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.BSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Compliance-57 (5) : intimation after the end of quarterBSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Compliance-57 (4) : Prior intimation to the beginning of the quarterBSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Intimation Of Non-Applicability Of Regulation 32(1) Of SEBI Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter Ended On 31St March 2026.BSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018BSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure ABSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Closure of Trading WindowBSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Announcement under Regulation 30 (LODR)-Newspaper PublicationBSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Dear Sir/Madam,
This Has Reference To Our Letter Dated January 28 2026.
1) The Board Has Considered And Approved The Unaudited Consolidated & Stand-Alone Financial Results Of The Company, For The Quarter Ended 31.12.2025 In Accordance With The Indian Accounting Standards (IND-AS) As Per Companies (Indian Accounting Standards) Rules, 2015.
2) Limited Review Report On The Unaudited Standalone And Consolidated Financial Results Of The Company, For The QuarteBSE · financial results · pdf
Source filing Transgene Biotek Ltd - 526139 - Board Meeting Outcome for Outcome Of Board MeetingBSE · financial results · pdf
Source filing Transgene Biotek Ltd - 526139 - Declaration Under Clause 36 Of Listing Agreement With BSE
PROHIBITORY ORDER NO. RRD/SRO/1166/2026/1 - SEBIBSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Board Meeting Intimation for Intimation Of The Board Meeting To Be Held On Friday, 13Th February, 2026BSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Statement Of Deviation & VariationBSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Compliance-57 (4) : Prior intimation to the beginning of the quarterBSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Compliance-57 (5) : intimation after the end of quarterBSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018BSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure ABSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Shareholder Meeting / Postal Ballot-Outcome of AGMBSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Shareholder Meeting / Postal Ballot-Outcome of AGMBSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportBSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Announcement under Regulation 30 (LODR)-Newspaper PublicationBSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Closure of Trading WindowBSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Reg. 34 (1) Annual Report.BSE · annual report · pdf
Archived filing Transgene Biotek Ltd - 526139 - Intimation Of Book Closure And Cut -Off Date For The 35Th Annual General Meeting Of Transgene Biotek Limited
With Reference To The Subject Cited, This Is To Inform That The Register Of Members And The Share Transfer Books Of The Company Will Remain Closed From Tuesday The 24Th December 2025 To Tuesday The 30Th December, 2025 (Both Days Inclusive) For The Purpose Of 35Th Annual General Meeting Which Is Scheduled To Be Held On Tuesday The 30Th December 2025 ABSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Announcement under Regulation 30 (LODR)-Newspaper PublicationBSE · financial results · pdf
Source filing Transgene Biotek Ltd - 526139 - Un-Audited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30, 2025. (Copy Enclosed)BSE · financial results · pdf
Source filing Transgene Biotek Ltd - 526139 - Board Meeting Outcome for Outcome Of Board Meeting Held On November 14, 2025.BSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Board Meeting Intimation for Intimation Of The Board Meeting To Be Held On Friday, 14Th November, 2025BSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Declaration Under Clause 36 Of Listing Agreement With BSE - Intimation About The Filing At NCLT (Hyderabad) Bench By M/S BABAJI NETHRALAYYA PRIVATE LTDBSE · exchange filing · pdf
Source filing Transgene Biotek Ltd - 526139 - Compliance-57 (4) : Prior intimation to the beginning of the quarterBSE · exchange filing · pdf
Source filing